Liver Safety Comparison of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Using Quantitative Systems Toxicology Software (DILIsym)

Conference: AAPS
Software: DILIsym®
Division: DILIsym Services


Lixivaptan, a vasopressin-2 receptor antagonist, is being developed for the treatment of autosomal-dominant polycystic kidney disease (ADPKD), an orphan disease that is an unmet medical need. We prospectively compared the potential for lixivaptan to cause liver toxicity to another drug in the same class, tolvaptan, which has produced off-target liver signals in clinical trials.

2018 AAPS Annual Meeting PharmSci 360, November 4-7, 2018, Washington, DC

By Howell, BA, Woodhead, JL, Pellegrini, L, Siler, SQ, Shoda, LKM